Format

Send to

Choose Destination

See 1 citation found by title matching your search:

AIDS. 2005 Jan 3;19(1):35-43.

Control of viral rebound through therapeutic immunization with DermaVir.

Author information

1
Research Institute for Genetic and Human Therapy, Washington, DC 20007, USA. lisziewj@geneticimmunity.com

Abstract

OBJECTIVE:

To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection.

DESIGN:

: A topical, DNA-based therapeutic immunization (DermaVir) was designed to express most of the regulatory and structural viral genes in dendritic cells.

METHODS:

DermaVir alone and in combination with antiretroviral drugs was tested in chronically SIV-infected macaques.

RESULTS:

DermaVir provided virological, immunological and clinical benefit for SIV-infected macaques during chronic infection and AIDS. In combination with antiretroviral drugs, DermaVir augmented SIV-specific T-cell responses and enhanced control of viral load rebound during treatment interruptions.

CONCLUSIONS:

The results indicate the feasibility of therapeutic immunization even in immune compromised hosts, and suggest that DermaVir can complement antiretroviral drugs to sustain suppression of HIV-1 replication.

PMID:
15627031
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center